← All trials
NCT05385705
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 11, 2022
- Primary completion
- Sep 11, 2024
- Completion date
- Apr 11, 2025
- First posted
- May 23, 2022
- Last posted
- Jun 1, 2022
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Universidad Autonoma de BarcelonaLead sponsor
- Banc de Sang i TeixitsCollaborator
- Universidad Autonoma de BarcelonaCollaborator
- Universidad Autonoma de BarcelonaOverall official - principal investigator
- Clinica Universidad de NavarraCollaborator
- Clinica Universidad de NavarraOverall official - principal investigator
- Autonomous University of MadridCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.